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Abstract
Background: Pneumonia is a main cause of  under-five mortality in low-income settings. The pneumococcal conjugate 
vaccine (PCV) has been introduced in many countries as a tool in the disease’s prevention. Although PCV’s effectiveness 
has been established, less is known about the effects of  introducing additional injectable vaccines into routine immunisation 
programmes, particularly in the context of  resource-constrained settings. 
Objectives: To explore the effects of  PCV introduction on the immunisation programmes and health systems in four 
low-income countries. 
Methods: This study was carried out in Cameroon, Ethiopia, Kenya and Mali. Three to four regions and nine to 10 dis-
tricts were selected within each country. Semi-structured interviews were carried out at national, regional and district levels 
(n=173). Researcher-administered questionnaires were completed with facility staff  (n=124). Routine data on monthly vac-
cination activities were collected at district and facility levels. 
Results: PCV was generally well integrated into existing routine immunisation. Little or no impact was found in most ar-
eas of  the health systems. Some minor effects were found on immunisation programmes, particularly in areas with either 
planning activities or investments e.g. staff  skills were strengthened and there were limited improvements in surveillance.
Although health sector workers perceived increases in the coverage of  other vaccines following the introduction of  PCV, 
routine service data did not confirm this claim. No substantial impacts were seen in health system management, service 
delivery or performance.   
Conclusions: The introduction of  PCV had marginal impacts on the Expanded Programme for Immunisation and little to 
none on broader health systems. 
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Introduction
Pneumonia is a main cause of  under-five mortality in 
low-income countries around the world; an estimat-
ed 540,000 children died from the disease in 2010 in 
sub-Saharan Africa1. The Streptococcus pneumoniae 
bacterium is a major cause of  pneumonia2, and of  oth-
er illnesses such as meningitis3. The effectiveness of  
pneumococcal conjugate vaccines (PCV) in preventing 
pneumonia has been established4,5 and the World Health 
Organization recommends the adoption of  PCV into 
vaccination programmes in developing countries with 
high pneumonia mortality rates6. With Gavi Alliance 
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support, over 25 countries introduced PCV since 2010 
and as many as 50 others had been approved for intro-
duction by October 20147. 
Children are offered three doses of  PCV at the same 
time as the diphtheria-tetanus-pertussis, hepatitis B, 
Haemophilius influenzae type b vaccine (pentavalent 
vaccine). PCV13 is offered in one-dose vials whilst 
PCV10 is provided in two-dose vials without preserva-
tive, raising concerns about the risk of  Adverse Events 
Following Immunisations (AEFIs) when first intro-
duced in low-income settings8. 
As more vaccines are added to routine immunisation 
schedules, questions have been raised regarding whether 
Expanded Programmes on Immunisation (EPI) would 
become overburdened. Previous studies either focused 
on demonstrating the health impact of  PCV4,5,9-11, or ex-
plored how new vaccines affected specific health system 
functions or vaccination coverage12,13. No research has 
evaluated the effects of  adding PCV into EPI nor how 
it, as one component of  the Integrated Global Action 
Plan for the Prevention and Control of  Pneumonia and 
Diarrhoea14, may have affected wider health systems. 
This paper aims to explore the impact of  PCV intro-
ductions on EPI and health systems in four countries 
in sub-Saharan Africa. The research was part of  a larg-
er study, exploring the impact of  introducing four vac-
cines in six low- and middle-income countries15. 
Methods
Cameroon, Ethiopia, Kenya and Mali were selected be-
cause they were early adopters of  PCV (Table 1). 
See Table 2 for background information on each coun-
try.
Data collection started between 5-13 months following 
introduction. Three to four regions were chosen in each 
country based on vaccination coverage (low, average 
and high compared to a national average). In Ethiopia 
four regions were selected to cover the range of  health 
administration directorates (urban, agrarian and pasto-
ral) as well as remote areas (Table 3). 
Table 1: PCV introduction characteristics 
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Country PCV 
type 
Date of vaccine 
introduction 
Data collection period Introduction strategy Catch up strategy Other relevant features 
Cameroon PCV13 July 2011 May – June 2012 Across the whole country at once None, but lack of 
understanding led some 
regions to vaccinate outside of 
the target group 
Upgraded cold chain using French debt relief programme funding. 
Pentavalent changed from 2 to 10 dose vial in March 2011. 
Meningitis A vaccination campaigns conducted in some regions in 4th quarter 2011 (not 
in study regions). 
Introduction occurred at a time of suspension of GAVI Alliance’s reward for 
performance. 
Ethiopia PCV10 November 2011 December 2012 – 
January 2013 
Across the whole country at once All <1 year old Health information systems were being reconfigured at time of introduction. 
Integrated Management of Childhood Illness training carried out a few months prior to 
introduction. 
Kenya PCV10 February 2011 July – August 2011; 
March – April 2012 
Across the whole country at once All <1 year old Additional health workers recruited (before and after introduction). 
Ongoing modernisation of cold chain. 
Reach Every District data quality trainings carried out (shortly before introduction). 
Pentavalent changed from 2 to 10 dose vials around the time of the PCV introduction. 
Polio and measles outbreaks led to vaccination campaigns during PCV planning. 
Mali PCV13 March-
December 2011 
March – June 2011; 
January 2012 
Phased over 9 months (March to 
November 2011) 
No catch up Numerous health campaigns conducted (14 in 2010 and 11 in 2011). 
Political unrest from March 2012. 
Introduced meningococcal A vaccine through campaigns around the same time as PCV. 
 




births (2011)26   
% of under-5 











total (% of 
GDP) (2011)26 
Cameroon 101 22 82 5.4 
Ethiopia 71 22 65 4.1 
Kenya 76 20 88 4.4 
Mali 132 24 72  6.8 
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Two to three districts were selected per region based on 
vaccination coverage and to represent a spectrum of  
urbanisation and rurality. Health facilities were selected 
based on increasing distance from the district centre. 
We aimed to sample at least three facilities per district, 
although more were sampled in Kenya districts and few-
er in some Ethiopian districts.  (Table 3). Government, 
private and faith-based health facilities were included. 
A mixed methods approach was used, including in-
terviews, questionnaires and the collection of  routine 
health service data. Semi-structured interviews were 
carried out with 173 key informants including EPI staff  
and health service managers at national, regional and 
district levels who had been involved in, or were knowl-
edgeable of, the PCV introduction. Researcher-admin-
istered questionnaires were completed with vaccination 
staff  in 124 facilities (see Table 3). 
Interviews were recorded, transcribed and, when neces-
sary, translated. Routine data was collected on monthly 
PCV and pentavalent vaccine uptake from facilities and 
districts. 
An adaptation of  the WHO’s health systems building 
blocks framework16,17 was used to structure the data 
collection tools.  However the findings will be present-
ed according to a framework adapted from the World 
Health Report 200018, since this was felt to be more ac-
tionable for countries introducing PCV or similar vac-
cines, as well as providing a more holistic perspective 
of  health systems levers (inputs, management, delivery, 
and performance)19. The questionnaire was adapted 
from the post introduction evaluation methodology20. 
Semi-structured interviews were analysed using the-
matic content analysis with the software ‘Open Code’21. 
Questionnaire data was analysed using descriptive sta-
tistics in SPSS software. Segmented regression analyses 
were conducted on the routine data to test statistical 
significance of  changes in trends of  utilisation of  other 
vaccinations following the introduction22. 
Ethical approval was obtained from LSHTM and rele-
vant national research ethics committees in each study 
country. Signed consent was obtained prior to data col-
lection. 
Results
PCV was generally well integrated into existing routine 
immunisation in study countries. Some interviewees ex-
plained that because PCV was added to the routine vac-
cination programme (as opposed to delivered through 
campaigns), it had an inherently positive impact, provid-
ing more focus on EPI. Little or no impact was found in 
most health system areas. Some minor and short-term 
effects were found on the immunisation programmes. 
These are discussed in more detail below.
Effects on health system inputs
The introduction had no effect on most inputs. Some 
positive effects were reported, particularly in staff  
strengthening and financial resource availability. Mi-
nor and temporary negative effects were found in staff  
workload and cold chain availability.
Staff 
Informants reported no changes in the number and 
distribution of  staff  during and following the PCV 
introductions. The proportion of  facility respondents 
reporting temporarily increased workload ranged from 
46% in Ethiopia to 93% in Kenya. Reasons for this in-
cluded; increased demand and greater time spent on 
sensitisation activities. There were also varying percep-
tions on whether time spent on general vaccination ac-
tivities since introduction had increased; from 12% in 
Ethiopia to 63% in Cameroon (Table 4). 
Cold chain 
Interviewees reported that existing cold chain was 
sufficient to accommodate PCV. Some explained that 
prior cold chain assessments and improvements had 
been critical to facilitate the introduction. Overall, key 
informants in Mali, Ethiopia and Cameroon (and 74% 
of  facility respondents across the four countries) said 
they coped with additional cold chain requirements. 
Some difficulties with cold chain were reported at dis-
trict levels in Mali and Cameroon, and at regional level 
in Ethiopia. These problems were resolved with adap-
tive strategies, such as more frequent deliveries from the 
regional level, or facilities picking up the vaccines from 
the district cold store on the delivery day. 
Some stock-outs of  PCV were reported in the first 1-3 
months after introduction. These were likely due to un-
clear directives on planning around catch-up strategies 
and target populations; initially some facilities reported-
ly gave out the vaccine to infants beyond the age range 
which had been planned for, depleting existing stocks 
quickly. The proportion of  facilities reporting stock-
outs varied: 8% in Ethiopia, 25% in Mali, 39% in Cam-
eroon and 51% in Kenya. The introductions were not 
thought to have caused stock-outs of  other vaccines.
Table 4: Perceived changes in workload 
  Cameroon Ethiopia Kenya Mali 
% of facility respondents who reported experiencing 
temporary increases in workload around the time of 
introduction 
60 46 93 52 
% of facility respondents who felt time spent on 
vaccination activities increased since PCV was 
introduced 
63 12 43 48 
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% of facility respondents who reported experiencing 
temporary increases in workload around the time of 
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Changes in the presentation of  the pentavalent vaccine 
(from 2-dose to 10-dose vials) around the time of  the 
PCV introductions created space for the new vaccines 
in Cameroon, Kenya and Mali. 
Financing
Key informants in Mali, Ethiopia and Kenya reported 
substantial increases in domestic allocation of  resourc-
es to support PCV introductions. No concrete effect 
on financing other health programmes was reported. 
Long-term financial sustainability was mentioned as a 
concern in Kenya, Cameroon and Ethiopia.
“With the new vaccines, the state will have to invest much more 
because these vaccines are expensive. The share of  co-financing by 
the government increases with Gavi reducing its financing... that 
is why it is important to advocate for the government to continue 
to invest in the vaccination programme…” National-level inter-
viewee, Cameroon 
Introduction funds were generally deemed sufficient. 
However, in Mali interviewees speculated that finan-
cial constraints delayed implementation, resulting in a 
phased introduction. All countries allocated additional 
funds for training. Some minor additional transporta-
tion and social mobilisation costs for outreach were re-
ported in Ethiopia and Cameroon at sub-national and 
facility levels, which were covered by local budgets.    
Skills
Most interviewees and 75% of  facility respondents 
said that training for PCV had strengthened staff  skills, 
notably injection administration skills, knowledge of  
AEFIs and social mobilisation techniques. Key inform-
ants in all countries stated that training covered broader 
topics than PCV, acting as a general EPI refresher and, 
in Ethiopia, also covering pneumonia prevention. How-
ever, at the facility-level about half  of  respondents per-
ceived the training to have been focused narrowly on 
PCV. The training was not reported to have disrupted 
routine activities. 
 
Effects on health system management
There were largely no effects reported on management 
as a result of  the PCV introduction. Some positive ef-
fects were seen in improved integration of  EPI and 
pneumonia prevention in Ethiopia and, to a lesser ex-
tent, in regulatory processes in Kenya. 
Management and planning
The planning processes for the introductions did not 
appear to have affected other health service activities 
in Cameroon, Ethiopia or Mali. In Kenya, the planning 
process coincided with a polio vaccination campaign 
following an outbreak, which was said to have creat-
ed challenges because the same officers were needed 
for both activities. In Ethiopia there was alignment 
between PCV introduction planning activities and oth-
er health systems planning. Input from sub-national 
levels at the planning stage was reported in Ethiopia 
and Kenya. In Ethiopia the inter-agency coordination 
committee (ICC) was reported to have been strength-
ened by the introduction, notably because of  active the-
matic sub-committees which continued to meet after 
PCV was introduced. There were no operational tech-
nical advisory committees on immunisation in the four 
countries at the time. 
Limited involvement of  stakeholders outside EPI was 
reported. There were some elements of  an integrated 
approach to the control of  pneumonia in Ethiopia, 
where interviewees mentioned specific collaboration 
between those planning Integrated Management of  
Childhood Illnesses (IMCI) strategies and EPI. A na-
tional IMCI training was implemented before the PCV 
introduction. In Mali a national integrated pneumo-
nia control workshop was organised but not followed 
up. Some limited collaboration was reported between 
health promotion, HIV and EPI in Kenya.
There were no changes reported in the frequency or 
organisation of  supervision. In Cameroon and Ethi-
opia additional supervisions were carried out in some 
regions immediately after the introductions. In Mali and 
Cameroon, targeted supervision activities were planned 
but not carried out because of  lack of  funds. Integrat-
ed supervision of  immunisation and other primary care 
activities was the norm in all countries.
There were no major changes reported on the accuracy 
or timeliness of  health information management sys-
tems apart from some initial delays in rolling out updat-
ed forms in all countries.
Regulatory processes
Changes to regulatory processes were reported by key 
informants in Kenya and Mali. In Kenya, the Pharmacy 
and Poisons Board was said to have been strengthened 
by the process of  registering the new vaccine and was 
seen as beneficial for future introductions. On the con-
trary, the national regulatory process was bypassed in 
Mali which, some argued, undermined domestic licens-
ing regulatory processes.
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Effects on service delivery
In general, service delivery was unchanged by the intro-
ductions. PCV was delivered as part of  routine child-
hood immunisation services. Ninety-five percent of  fa-
cility respondents stated that there had been no change 
in the number of  vaccination sessions offered, 92% 
stated that the pattern of  outreach vaccination sessions 
remained unchanged, and 85% explained that the type 
of  service package delivered alongside vaccination ser-
vices had not changed. 
Effects on health system performance
In general, no effect was seen on health system perfor-
mance, although some improvements in staff  morale 
were reported. 
Health service coverage
There was a stark contrast between perceptions of  the 
effect of  the new vaccine on uptake of  other routine 
vaccines and findings from the routine data. Many key 
informants and 78% of  health facility respondents per-
ceived changes in the total number of  children vaccinat-
ed for other diseases following the PCV introduction. 
These views were particularly strong in Kenya. How-
ever, segmented regression analyses of  routine data 
showed no changes in the monthly number of  children 
vaccinated with the first dose of  the pentavalent vac-
cine in Kenya, Ethiopia and Cameroon before and after 
the introduction. An increase in coverage of  the first 
dose of  the pentavalent vaccine was initially observed 
in Mali, although only in the short term (see Figure 1). 
Interviewees, and 54% of  facility respondents, believed 
that offering PCV had enabled them to better trace vac-
cine defaulters. 
“It strengthens the coverage of  other vaccines... because when they 
were mobilising for PCV, it opened a door for finding defaulters 
when the health extension workers went house to house. So they 
bring them.” District-level interviewee, Ethiopia
“We were able even to get children who...were not immunised 
with other vaccines because, as you know, in Kenya pneumonia is 
feared.” District-level interviewee, Kenya 
Adverse Effects Following Immunisation reporting
Despite global interest in AEFIs related to PCV, as well 
as attention paid to surveillance and AEFI training, no 
changes in the number of  registered AEFIs for any vac-
cine was reported. Some key informants explained that 
AEFIs were routinely underreported.
Many interviewees stated that the PCV introductions 
placed a strong emphasis on AEFI surveillance, par-
ticularly at the national level in Ethiopia and Kenya, 
where preservative-free PCV10 was introduced. The 
introduction was seen as a catalyst for AEFI surveil-
lance in Ethiopia, where key informants mentioned that 
four sentinel sites were set up for a year post-introduc-
tion. In Cameroon, the PCV introduction resulted in 
additional funding for surveillance, including laboratory 
strengthening and training of  laboratory staff.
Vaccine acceptance
All countries benefited from strong political support 
and social mobilisation activities during PCV introduc-
tion. 
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Figure 1: Number of children vaccinated with the first dose of the pentavalent vaccine before 
and after PCV introductions 
 
 































13 facilities Structural trend
Months 







































































34 facilities Structural Trend
Months 
Messages were said to have focused narrowly on PCV 
in Cameroon and Ethiopia while addressing wider ben-
efits of  vaccination in Kenya and Mali. Facility staff  re-
ported strong parental acceptance of  PCV in all coun-
tries because pneumonia was known and feared. Health 
worker and parental concerns about injecting the child 
with both pentavalent and PCV in the same visit were 
reported at the time of  introduction, but subsided rap-
idly.
Staff  morale
All countries reported increased staff  morale resulting 
from the PCV introduction; the expected decrease in 
pneumonia was considered a motivational factor. 
Discussion
Our findings show remarkable consistency across the 
four countries. PCV was generally well integrated into 
existing routine immunisation programmes. Overall 
no impact was seen on most aspects of  health system 
inputs, although some positive effects were reported 
on staff  skills and the availability of  financial resourc-
es. Some temporary negative effects were reported on 
staff  workload and cold chain. Generally no effect was 
reported on health system management, although there 
were some country-specific positive effects in disease 
prevention integration and regulatory procedures. Ser-
vice delivery largely remained unchanged. There was 
generally no effect on health system performance, al-
though some positive effects on staff  morale and AEFI 
surveillance were reported. 
There was a perception in all four countries that the 
new vaccine enhanced the coverage of  other vaccines. 
However, routine data did not confirm any lasting 
change in vaccination coverage. This is in line with pre-
vious findings on the impact of  pentavalent vaccine on 
vaccination coverage12. Perceptions of  increased uptake 
might have been observed because catch-up strategies 
were deployed in Kenya, Ethiopia and in some regions 
of  Cameroon where the target population had been un-
clear, meaning that more children had come to be vac-
cinated for PCV in the period immediately after intro-
duction. The main differences between Mali and other 
countries were that it had a phased introduction and 
involved no catch-up strategy. 
Similarities between the four countries may reflect com-
mon goals in their EPIs, a shared Gavi Alliance appli-
cation processand standard introduction preparations. 
Stronger emphasis was placed on a more integrated ap-
proach to pneumonia prevention and control in Ethio-
pia, where child health and vaccination activities were 
incorporated into each geographical directorate of  the 
Ministry of  Health, leading to more integrated activi-
ties. It has previously been argued that without more 
emphasis on other strategies to combat pneumonia be-
yond vaccination, countries will not achieve expected 
reductions in child mortality23. 



































19 facilities Structural trend
Months 
Limited or no effects were seen in programme areas that 
received no additional funding and/or were left out of  
technical planning. These included changes in delivery 
models and general collaborative activities beyond EPI 
(e.g. integrated approach to pneumonia control, co-de-
livery of  interventions). These findings suggest that if  
policymakers want to see greater positive impacts of  
introducing new vaccines, more long-term engagement, 
collaboration and financing13,24 is needed. It is unlikely 
that a new vaccine introduction, which is focused on 
achieving targeted high population coverage, may foster 
such structural changes, unless a deliberate strategy is 
developed. Those hoping to use introductions as op-
portunities to strengthen EPI should consider this in 
the early planning stages of  introduction, as outlined by 
WHO in their recently updated guidance on new vac-
cine introductions25.
Although our findings suggest that there were no long-
term negative effects to the PCV introduction, ques-
tions remain about the limits of  health systems to ab-
sorb new interventions. As new vaccine introductions 
continue apace, further research will be needed to better 
gauge the limits of  the systems’ absorptive capacities. 
Strengths and limitations
This study used several methods, enabling triangulation 
of  findings. This was particularly useful in the case of  
pentavalent vaccine coverage. However the study was 
also limited by poor quality, or absent, routine data 
and the inability to gather post-introduction data for a 
full year in all countries. These findings might not be 
generalisable for all vaccine introductions; effects of  
introductions depend on the delivery methods, target 
populations and general context of  the EPI and health 
system.
Data collection tools were structured around the 
WHO’s health systems building blocks framework. Al-
though advantageous for its wide scope, the framework 
lacks a health services demand component19. This study 
focused on the impact on the health system and did not 
include the impact of  PCV introductions on commu-
nities’ acceptance and perceptions of  other vaccines or 
confidence in the health system. Further work in this 
area is needed.  
Conclusion
The introduction of  PCV had no overall effect on the 
EPI or health system levers. However there were some 
positive effects, such as a boost to staff  morale, staff  
training and financial resource availability. Although 
there were some negative impacts, such as increased 
workload, these tended to be only temporary. This lack 
of  long-term negative impacts is noteworthy, given 
previous questions about the risks of  overburdening 
already weak health systems. The greatest effects were 
felt in areas with either planning activities and/or in-
vestments. Those hoping for greater positive impacts 
of  new vaccine introductions should use the planning 
process to leverage broader approaches that may lead to 
greater effects both within and beyond EPI.   
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